Influenza, aka “the flu,” infected 35 million Americans in 2018-19, according to the Centers For Disease Control. Those numbers included 491,000 hospitalizations and 34,200 deaths. The 2017-18 flu season featured 45 million infections, 810,000 hospitalizations and 61,000 deaths. The CDC estimated upwards of 56 million illnesses, 740,000 hospitalizations and 62,000 deaths for the 2019-20 flu season.
The headlines are incredible. ABC13 in Toledo, Ohio reported on January 25 that only two people had been hospitalized with the flu so far this season. That number was 205 people at the same time in 2020. NBC News 9 in Denver reported on Sunday that only 30 people had been hospitalized with the flu in the entire state of Colorado in the 2020-21 season. The entire state of Pennsylvania has reported 41 flu hospitalizations and 17 deaths for the entire 2020-21 flu season.
The headlines are incredible. ABC13 in Toledo, Ohio reported on January 25 that only two people had been hospitalized with the flu so far this season. That number was 205 people at the same time in 2020. NBC News 9 in Denver reported on Sunday that only 30 people had been hospitalized with the flu in the entire state of Colorado in the 2020-21 season. The entire state of Pennsylvania has reported 41 flu hospitalizations and 17 deaths for the entire 2020-21 flu season.
The CDC is reporting a total of 1,710 total flu infections in the United States from September 27, 2020 to April 3, 2021.
Meanwhile the CDC is reporting over 31 million “COVID-19” cases in the United States since the disease started in March 2020. Or shall we say, since the rebranding campaign began.
Rebranding has several purposes. Some companies need to escape bad publicity. Others simply need a makeover to keep up with market trends. But the bottom line for all rebranding campaigns is money. That is no different for the flu-to-COVID-19 rebranding campaign.
The global flu vaccine market was worth $4 billion total in 2015. That is a paltry sum compared to what COVID-19 shots will generate. CNN Business projects that Pfizer and Moderna will generate $32 billion from experiment shots in 2021 alone. Johnson & Johnson (Janssen Pharmaceuticals) is expected to generate $10 billion from its shots in 2021.
No comments:
Post a Comment